Home
HFL
News
Events
Publications
Careers
Volunteer
Contact
Search this site:
Our Clinical Services
Phase I/IIa
Drug Product Optimisation
14C Enabled Drug Development
Human ADME
Light Label ADME studies
Microdosing
Microtracer and ivMicrotracer studies
Synthesis-to-Clinic
Our Clinical Capabilities
Unique Clinical Platforms
Synthesis-to-Clinic
Accelerate early drug development with our Synthesis-to-Clinic service
Anti-infective Studies
Understand how anti-infective studies impact on your clinical trials
Clinical
>
14C Enabled Drug Development
14C Enabled Drug Development
Unique
Synthesis-to-Clinic™
platform
World-leading expertise in traditional and light-label
human ADME
iv
Microtracer™
and Phase 0
microdosing
studies
